|
Real-time Estimate
Cboe BZX
14:29:13 2026-09-21 EDT
|
5-day change | 1st Jan Change | ||
| 25.28 USD | +7.05% |
|
+5.44% | -5.86% |
| 08-18 | Barclays Adjusts Price Target on Amphastar Pharmaceuticals to $23 From $20, Maintains Equalweight Rating | MT |
| 08-07 | Amphastar Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 1B | |||||
| 1,028B | |||||
| 651B | - | ||||
| 466B | |||||
| 346B | |||||
| 266B |
Select your edition
All financial news and data tailored to specific country editions
